PDT’s Public Market Pivot: Survival Beyond Prescriptions

The promise of prescription digital therapeutics (PDTs) to deliver clinically validated software-based interventions has long captivated investors. Yet, the public market journey for these innovative companies has been anything but smooth, forcing a dramatic restructuring of business models in the face of formidable commercialization hurdles. This report digs into the financial survival strategies of public PDT players, analyzing their pivot away from prescription-only models and toward more diversified, often direct-to-consumer approaches.

The Commercial Struggle of Prescription Models

The initial vision for PDTs mirrored that of traditional pharmaceuticals: strong clinical trials leading to regulatory clearances, followed by physician prescriptions and insurer reimbursement. This pathway, while theoretically sound, encountered significant friction in practice. Low insurer adoption, coupled with the high costs associated with traditional pharmaceutical-style sales forces and market access teams, created an unsustainable burn rate for many early entrants. The challenge was not just proving clinical efficacy, but translating that efficacy into a scalable and financially viable distribution and reimbursement model within a healthcare system notoriously slow to embrace novel digital solutions. The core issue has been the difficulty in securing broad, consistent reimbursement, a critical component for any prescription-based therapy. Without clear CPT codes or established payment pathways, adoption by health systems and individual prescribers remains constrained. This lack of a clear reimbursement moat has exposed PDT companies to significant financial strain, forcing a re-evaluation of their go-to-market strategies.

Akili’s Strategic Pivot: From Prescription to Over-the-Counter

Akili Interactive, a pioneer in the PDT space with its FDA-cleared EndeavorRx for ADHD, provides a stark illustration of this commercial struggle and the subsequent strategic pivot. Despite achieving 510(k) clearance for a novel therapeutic FDA 510(k) database for EndeavorRx, the company faced an uphill battle in translating regulatory success into significant revenue. The initial prescription-only model, while aligning with the “digital therapeutic” moniker, proved challenging to scale. Analyzing Akili Interactive’s quarterly revenue and cash burn from SEC 10-K and 10-Q filings reveals the acute pressure. For instance, Akili reported total revenues of $749 thousand for Q4 2023 and $383 thousand for Q1 2024. GAAP total operating expenses were $12.1 million for Q4 2023 and $11.1 million for Q1 2024, resulting in continued net losses and cash burn. This financial trajectory underscored the unsustainability of their initial approach. In response, Akili announced a significant strategic shift in late 2023: a transition to an over-the-counter (OTC) model for EndeavorRx. This move, while requiring a new regulatory pathway and market strategy, aims to bypass the complexities and delays of physician prescription and insurer reimbursement. In June 2024, Akili received FDA clearance for EndeavorOTC, an over-the-counter treatment for adults with ADHD, further solidifying its pivot to a direct-to-consumer model. By making EndeavorRx directly available to consumers, Akili hopes to unlock a larger, more accessible market, shifting the burden of adoption from the healthcare system to the individual consumer. This pivot represents a fundamental rethinking of how therapeutic software can achieve commercial scale, moving closer to a direct-to-consumer software subscription model rather than a traditional pharmaceutical one. The financial impact of this shift, particularly on marketing spend versus sales force costs, will be a critical indicator for future PDT models. However, this strategic shift culminated in Akili’s acquisition by Virtual Therapeutics in 2024, transitioning the company to a privately held subsidiary and removing its stock from public exchanges.

Better Therapeutics: Restructuring for Survival

Another public PDT company, Better Therapeutics, provides further evidence of the intense financial pressures in the sector. Focused on digital therapeutics for cardiometabolic diseases, Better Therapeutics also secured FDA authorization for AspyreRx, a PDT for type 2 diabetes Better Therapeutics AspyreRx FDA authorization details. However, similar to Akili, the company encountered significant commercial headwinds. Public digital therapeutics stock performance across the sector has reflected these challenges, with many companies experiencing substantial declines from their initial public offering valuations. Better Therapeutics’ journey exemplifies the need for drastic measures to manage cash burn and extend runway. Faced with a difficult capital environment and slower-than-anticipated commercial uptake, the company underwent a significant restructuring of operations. In March 2024, Better Therapeutics announced its decision to wind down operations, terminate employees, and seek strategic alternatives, including asset sales, leading to its delisting from Nasdaq and subsequent trading on the OTC market. This drastic measure shows the severe financial viability challenges faced by the company. While painful, such restructuring is a common tactic for companies to realign their cost base with revenue realities and market opportunities. The ultimate goal is to achieve a leaner operating model that can either sustain itself through organic growth or become an attractive acquisition target. The challenge for investors is discerning whether these restructurings are merely delaying the inevitable or laying the groundwork for a viable, albeit smaller, enterprise.

Viable Business Models for Therapeutic Software

The experiences of Akili and Better Therapeutics offer critical lessons for public equity analysts and distressed asset investors evaluating the digital therapeutics space, particularly as AI trends in healthcare continue to accelerate. The initial “pharma-like” commercialization model for PDTs has proven to be a high-burn, low-return strategy. The future of AI in healthcare trends 2026 and beyond suggests a diversification of commercial pathways for therapeutic software. Viable business models for therapeutic software appear to be coalescing around several key strategies:

• Direct-to-Consumer (DTC) / Over-the-Counter (OTC) Models: Bypassing traditional prescription channels to reach consumers directly, using digital marketing and subscription revenue. This requires a strong consumer brand and clear value proposition.
• Enterprise Partnerships: Integrating therapeutic software into health systems, payers, or large employers, often as a value-added service to existing care pathways. This shifts the sales cycle from individual prescribers to organizational buyers.
• Hybrid Models: Combining elements of both DTC and prescription, offering different access points based on product, market, and regulatory status.
• Platform Integration: Becoming a bolt-on acquisition for larger healthcare technology companies or pharmaceutical firms seeking to expand their digital offerings.

The focus for investors should shift from simply evaluating clinical evidence and regulatory clearances to scrutinizing the commercialization strategy and its associated unit economics. Companies that can demonstrate a clear path to scalable revenue generation without excessive cash burn, or those with a demonstrable data moat that commands pricing power, will be best positioned. The healthcare AI trends are increasingly favoring solutions that can integrate smoothly into existing workflows or offer a compelling consumer experience with minimal friction.

Methodology and Source Note

This analysis is based on a review of public SEC 10-K and 10-Q filings for Akili Interactive and Better Therapeutics, alongside publicly available stock performance data. The financial figures cited are derived directly from these official company disclosures, providing a transparent and verifiable basis for our conclusions. Our approach prioritizes a financial performance review to assess the commercial viability and survival strategies within the public digital therapeutics sector.